# Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

> **NCT02165345** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 82 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT02165345
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-16
- **Primary completion:** 2021-11-24
- **Final completion:** 2021-11-24
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2022-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02165345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02165345, "Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02165345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*